دورية أكاديمية
Biological background of the genomic variations of cf-DNA in healthy individuals.
العنوان: | Biological background of the genomic variations of cf-DNA in healthy individuals. |
---|---|
المؤلفون: | Liu J; Tianjin Medical Laboratory, BGI-Tianjin, Tianjin; School of Bioscience and Bioengineering, South China University of Technology, Guangzhou., Chen X; Binhai Genomics Institute, BGI-Tianjin, Tianjin., Wang J; BGI-Shenzhen, Shenzhen; James D. Watson Institute of Genome Sciences, Hangzhou., Zhou S; Tianjin Medical Laboratory, BGI-Tianjin, Tianjin., Wang CL; Tianjin Medical Laboratory, BGI-Tianjin, Tianjin., Ye MZ; BGI-Guangzhou, BGI-Shenzhen, Guangzhou., Wang XY; Tianjin Medical Laboratory, BGI-Tianjin, Tianjin., Song Y; Tianjin Medical Laboratory, BGI-Tianjin, Tianjin., Wang YQ; Tianjin Medical Laboratory, BGI-Tianjin, Tianjin., Zhang LT; Tianjin Medical Laboratory, BGI-Tianjin, Tianjin., Wu RH; Tianjin Medical Laboratory, BGI-Tianjin, Tianjin., Yang HM; BGI-Shenzhen, Shenzhen; James D. Watson Institute of Genome Sciences, Hangzhou., Zhu SD; BGI-Shenzhen, Shenzhen., Zhou MZ; BGI-Guangzhou, BGI-Shenzhen, Guangzhou., Zhang XC; The Affiliated Hospital of Qingdao University, Qingdao, China., Zhu HM; Binhai Genomics Institute, BGI-Tianjin, Tianjin. Electronic address: zhuhongmei@genomics.cn., Qian ZY; Binhai Genomics Institute, BGI-Tianjin, Tianjin. Electronic address: qianzy@mail.ustc.edu.cn. |
المصدر: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Mar 01; Vol. 30 (3), pp. 464-470. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2020- : London : Elsevier Original Publication: Dordrecht ; Boston : Kluwer Academic Publishers, c1990- |
مواضيع طبية MeSH: | Prognosis*, Cell-Free Nucleic Acids/*blood , Clonal Evolution/*genetics , Hematologic Neoplasms/*blood, Aged ; Cell-Free Nucleic Acids/genetics ; DNA (Cytosine-5-)-Methyltransferases/genetics ; DNA Methyltransferase 3A ; DNA-Binding Proteins/genetics ; Dioxygenases ; Gene Frequency/genetics ; Genome, Human/genetics ; Genomics ; Healthy Volunteers ; Hematologic Neoplasms/genetics ; Hematologic Neoplasms/pathology ; Hematopoiesis/genetics ; Humans ; Janus Kinase 2/genetics ; Middle Aged ; Mutation/genetics ; Proto-Oncogene Proteins/genetics |
مستخلص: | Background: Cell-free DNA (cf-DNA)-based liquid biopsy is emerging as a revolutionary new method in individualized cancer treatment and prognosis monitoring, although detecting early-stage cancers using cf-DNA remains challenging, partially because of the undefined biological background of cf-DNA. Materials and Methods: We investigated somatic mutations in the cf-DNA of 259 cancer-free individuals with a median age of 47 years using an endogenous barcoding duplex method with an ultralow base error rate (2 × 10-7) and compared the variant allele frequencies (VAFs) of these mutations between the cf-DNA and the corresponding blood cell DNA. Results: Sixty percent (155/259) of the samples showed at least one nonsynonymous mutation on either of two similar target panels covering 508 and 559 cancer-related genes. For individuals older than 50 years of age, the positive rate increased to 76%. Most cf-DNA mutations were also present at similar VAFs in the paired blood cell DNA. The most frequently mutated genes were driver genes of hematologic malignancies, including DNMT3A, TET2, AXSL1, and JAK2. However, the other 58.4% (192/329) of the mutations were likely 'passenger mutations' of clonal hematopoiesis, including mutations in NOTCH2, FAT3, EXT2, ERBB4, and ARID2, which are driver genes of solid tumors. Conclusion: Hematopoietic clone-derived mutations, including 'driver mutations' and 'passenger mutations', are prevalent in the cf-DNA of both healthy individuals and cancer patients and may be a potential source of false positives in the liquid biopsy. Our results also suggest the ineffectiveness for distinguishing clonal hematopoietic mutations of low VAF (≤0.1%) from tumor-derived mutations using conventional next-generation sequencing of blood cell DNA. However, an error correction model with an ultralow error rate and high coverage depth is required for blood cell DNA sequencing, which is difficult and costly to achieve with current technologies. (© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.) |
التعليقات: | Comment in: Ann Oncol. 2019 Mar 1;30(3):358-359. (PMID: 30649226) |
فهرسة مساهمة: | Keywords: biological background; cf-DNA; duplex sequencing; early cancer diagnosis; hematopoietic clone; mutation |
المشرفين على المادة: | 0 (Cell-Free Nucleic Acids) 0 (DNA-Binding Proteins) 0 (DNMT3A protein, human) 0 (Proto-Oncogene Proteins) EC 1.13.11.- (Dioxygenases) EC 1.13.11.- (TET2 protein, human) EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases) EC 2.1.1.37 (DNA Methyltransferase 3A) EC 2.7.10.2 (JAK2 protein, human) EC 2.7.10.2 (Janus Kinase 2) |
تواريخ الأحداث: | Date Created: 20181127 Date Completed: 20200324 Latest Revision: 20211204 |
رمز التحديث: | 20240628 |
DOI: | 10.1093/annonc/mdy513 |
PMID: | 30475948 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1569-8041 |
---|---|
DOI: | 10.1093/annonc/mdy513 |